The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in September 2004
Cytyc Corp. and The University of Massachusetts Medical School are collaborating to commercialize the technology, which focuses on centrosomes in cancerous and pre-cancerous cells, developed by Stephen J. Doxsey, Ph.D., associate professor of molecular medicine, biochemistry & molecular pharmacology, and cell biology at UMMS. The agreement gives Cytyc a worldwide exclusive license to use Doxsey's technology for developing products in the areas of cancer diagnostics and prognostics.
DiaSys Corporation introduced a new line of 47 ELISA products of which 18 are now FDA approved and CE marked for tumor markers, cardiac markers, steroid, anemia, fertility hormones, growth hormone, allergy and thyroid tests.
Diagnostic Products Corporation and Compugen Ltd. announced a collaboration for the development and commercialization of products for cancer and cardiovascular diseases.
HemoSense, Inc. signed an exclusive agreement with Medline Industries, Inc. to distribute HemoSense's INRatio Prothrombin Time (PT) Monitoring System to alternate care, home health care, and nursing home care facilities in the US.
Nanogen, Inc. has merged with Epoch Biosciences, Inc. Epoch has a variety of products that are complementary to Nanogen's, and the merger will expand Nanogen's reach in the rapidly growing clinical lab and research markets.
Quest Diagnostics signed an exclusive distribution agreement with Veridex, LLC, a Johnson & Johnson company, to offer Veridex's CellSearch Circulating Tumor Cell Kit, a new cancer diagnostic technology that identifies and counts circulating tumor cells in blood samples from patients being treated for metastatic breast cancer.
Ventana Medical Systems, Inc. and Quantum Dot Corporation (QDC) are collaborating to adapt QDC's Qdot nanocrystal technology for in vitro diagnostic applications in histology and cytology. Ventana also signed a five-year global supply agreement with TriPath Imaging Inc. Under the agreement, Ventana obtained exclusive rights to sell and distribute worldwide a Ventana-branded version of TriPath Imaging's histology imaging system that will be optimized for Ventana and TriPath Imaging assays.
Product developments - Summer 2004
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: October 06, 2004